The plant in Baltimore, Maryland, US is now ready for Cel-Sci to begin manufacture of its cancer drug Multikine (Leukocyte interleukin injection) in preparation for a head and neck Phase III clinical trial.
Also, Cel-Sci is now ready to offer contract manufacturing services from the facility and these could begin once it has produced the material required for the Phase III trial.
This could provide an additional revenue stream as Cel-Sci awaits Multikine’s regulatory approval and attempts to recoup some of the $22m (€15m) it cost to build the facility.